DNER and leukemia: The efficacy of BET inhibitors was mainly explored in hematologic malignancies and pediatric cancers where well known transcription factors play a key role in the oncogenesis of the disease, as is the case of C-MYC in neuroblastomas or leukemia [18, 21].